Combining the targeted therapy olaparib with an additional immunotherapy may improve immune response in a subgroup of ...

Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they need to grow. Weill Cornell ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...

Over the past year alone, 4 major clinical trials have redefined frontline HSPC management. ARANOTE ( NCT02799602) v alidated ...

Lu-177 vipivotide tetraxetan shifted from post-taxane mCRPC to pre-chemotherapy mCRPC and then metastatic hormone-sensitive ...

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer -such as ...

Hormone Therapy Might Be Unnecessary For Some Prostate Cancer Patients By Dennis Thompson HealthDay ReporterMONDAY, March 2, 2026 (HealthDay News) — Some men who’ve had surgery for prostate cancer can ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...

Opevesostat (Merck). A first-in-class CYP11A1 inhibitor that shuts down androgen production at its source, opevesostat is in two phase 3 trials, OMAHA-003 and OMAHA-004, for metastatic ...